인쇄하기
취소

Alteogen challenges to KRW 2 trillion hemophilia biomedicine ‘NovoSeven’

Published: 2016-12-01 11:50:42
Updated: 2016-12-01 11:50:42

Alteogen Inc.(CEO Soon-Jae Park) held an agreement ceremony on the 29th of November as its long-acting hemophilia treatment being developed, ‘ALT-Q2,’ was selected as a project to develop a substance candidate for a preclinical trial from the Korea Drug Development Fund(CEO Sang-Aun Joo).

ALT-Q2 is a long-acting hemophilia treatment applied with Factor VII, a hemophilia treatment integrated wi...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.